PHEOCHROMOCYTOMA/PARAGANGLIOMA (PPGL)
Clinical trials for PHEOCHROMOCYTOMA/PARAGANGLIOMA (PPGL) explained in plain language.
Never miss a new study
Get alerted when new PHEOCHROMOCYTOMA/PARAGANGLIOMA (PPGL) trials appear
Sign up with your email to follow new studies for PHEOCHROMOCYTOMA/PARAGANGLIOMA (PPGL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New scan could spot hidden cancers better than current methods
Diagnosis Recruiting nowThis study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…
Matched conditions: PHEOCHROMOCYTOMA/PARAGANGLIOMA (PPGL)
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
New scan could spot rare tumors better than current gold standard
Diagnosis Recruiting nowThis study tests a newer type of PET/CT scan (Al18F-NOTA-LM3) against the current standard (68Ga-DOTATATE) to see which finds more tumors in people with pheochromocytoma or paraganglioma (PPGL). About 40 adults with suspected or confirmed PPGL will receive both scans, and doctors…
Matched conditions: PHEOCHROMOCYTOMA/PARAGANGLIOMA (PPGL)
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC